Answers are grounded in this paper and cite their sources.
WHAT IS KNOWN AND OBJECTIVE: Daratumumab, an anti-CD38 monoclonalantibody, is a safe and effective antibody used in the treatment of multiple myeloma (MM), which is rarely reported to cause severe pulmonary complications. CASE SUMMARY: A 58-year-old man diagnosed with MM and preexisting interstitial lung disease developed a high fever and severe dyspnea after administering Daratumumab and bortezomib-containing regimen. Chest CT showed bilaterally and diffused ground-glass opacities and consolidations. A quick improvement was achieved in both clinical symptoms and chest imaging findings through the administration of large doses of methylprednisolone, followed by oral prednisolone. WHAT IS NEW AND CONCLUSION: This is the first case reporting Daratumumab and bortezomib-containing regimen-induced lung injury characterized by preexisting interstitial lung disease.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: